Enfortumab Vedotin + Pembrolizumab

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Bladder Squamous Cell Carcinoma

Conditions

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm, Malignant Urethral Neoplasm, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Unresectable Bladder Carcinoma, Urachal Adenocarcinoma, Bladder Adenocarcinoma

Trial Timeline

Sep 26, 2023 → Dec 16, 2027

NCT ID

NCT05756569

About Enfortumab Vedotin + Pembrolizumab

Enfortumab Vedotin + Pembrolizumab is a phase 2 stage product being developed by Astellas Pharma for Bladder Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05756569. Target conditions include Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm.

What happened to similar drugs?

20 of 20 similar drugs in Bladder Squamous Cell Carcinoma were approved

Approved (20) Terminated (1) Active (0)

✅mirabegron + solifenacinAstellas PharmaApproved

✅Mirabegron + PlaceboAstellas PharmaApproved

✅SolifenacinAstellas PharmaApproved

✅Mirabegron + Tolterodine ERAstellas PharmaApproved

✅Alpha blocker + placebo + solifenacinAstellas PharmaApproved

✅Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07475806	Phase 2	Recruiting	Mar 31, 2026	Apr 30, 2031	Muscle-invasive Bladder Cancer
NCT06906822	Phase 2	Recruiting	Jun 10, 2025	Jun 1, 2028	Melanoma
NCT06809140	Phase 2	Recruiting	Apr 7, 2025	Nov 1, 2029	Muscle Invasive Bladder Urothelial Carcinoma
NCT06470282	Phase 1/2	Recruiting	Mar 31, 2025	Jan 31, 2028	Bladder Cancer
NCT05756569	Phase 2	Recruiting	Sep 26, 2023	Dec 16, 2027	Bladder Squamous Cell Carcinoma
NCT05239624	Phase 2	Recruiting	Jun 2, 2022	Jun 1, 2027	Urothelial Carcinoma
NCT04225117	Phase 2	Active	Mar 9, 2020	Sep 30, 2026	Locally Advanced or Metastatic Malignant Solid Tumors

Competing Products

20 competing products in Bladder Squamous Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
pegylated liposomal doxorubicin (PLD) + PD-1	CSPC Pharmaceutical Group Limited	Phase 2	31
EG-70 (phase 1) + EG-70 (phase 2)	enGene	Phase 1/2	29
mirabegron + solifenacin	Astellas Pharma	Approved	43
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
Enfortumab vedotin	Astellas Pharma	Phase 1	21
Mirabegron + Placebo	Astellas Pharma	Approved	43
Solifenacin	Astellas Pharma	Approved	43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to Tolterodine	Astellas Pharma	Phase 3	40
solifenacin succinate	Astellas Pharma	Phase 3	40
Solifenacin	Astellas Pharma	Pre-clinical	26
Betanis	Astellas Pharma	Pre-clinical	26
Solifenacin	Astellas Pharma	Approved	43
Solifenacin	Astellas Pharma	Phase 2	35
Mirabegron + Tolterodine ER	Astellas Pharma	Approved	43
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverine	Astellas Pharma	Pre-clinical	26
Enfortumab vedotin + Pembrolizumab	Astellas Pharma	Phase 2	42
MK-3475 + ASG-22CE	Astellas Pharma	Phase 2	42
Alpha blocker + placebo + solifenacin	Astellas Pharma	Approved	43
warfarin + YM178	Astellas Pharma	Phase 1	29
Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin	Astellas Pharma	Phase 3	40